Antibody drug conjugates and bispecifics seize the spotlight at ASCO 2022
Clarivate
JUNE 23, 2022
In fact, it was a very small trial of an old-fashioned anti-PD-1 mononoclonal antibody, dostarlimab (AKA Jemperli), that garnered most of the headlines outside of the specialty titles. Jemperli, developed by GlaxoSmithKline, has been marketed in the U.S. since April, 2021 for treatment of endometrial cancer and certain solid tumors.
Let's personalize your content